Guardant Health (NASDAQ:GH) Upgraded at Mizuho

Guardant Health (NASDAQ:GH) was upgraded by equities researchers at Mizuho to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Several other brokerages have also issued reports on GH. Scotiabank boosted their price target on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Stephens reiterated an “overweight” rating and set a $55.00 target price on shares of Guardant Health in a research report on Wednesday, March 26th. Barclays cut their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Thursday. Guggenheim reaffirmed a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Guardant Health presently has an average rating of “Buy” and a consensus price target of $49.00.

Guardant Health Stock Performance

Shares of NASDAQ GH traded up $0.35 during midday trading on Wednesday, reaching $41.49. The stock had a trading volume of 26,061 shares, compared to its average volume of 2,127,150. The company’s 50 day moving average price is $43.64 and its 200 day moving average price is $35.54. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The firm has a market cap of $5.12 billion, a price-to-earnings ratio of -11.69 and a beta of 1.45.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Equities analysts forecast that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently made changes to their positions in GH. Vanguard Group Inc. increased its position in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after acquiring an additional 350,606 shares during the last quarter. Deep Track Capital LP increased its position in shares of Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock valued at $196,118,000 after purchasing an additional 419,006 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after purchasing an additional 1,138,300 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of Guardant Health by 38.5% in the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock worth $57,761,000 after buying an additional 525,368 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.